DeepMed Research

Imperial College London

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Private

Established: 1907-07-08

Employees: 5K

Market Cap: -

Website: http://www.imperial.ac.uk

Clinical Trials

Lutathera and ASTX727 in Neuroendocrine Tumours

Phase 1

Recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: ASTX727
Radiation: Lutathera

First Posted Date: 2022-01-05

Last Posted Date: 2025-05-02

Lead Sponsor: Imperial College London

Target Recruit Count: 27

Registration Number: NCT05178693

Locations: 🇬🇧
Hammersmith Hospital, London, London, City of, United Kingdom

Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.

Phase 4

Completed

Conditions: Addiction Opiate

Interventions: Drug: Baclofen
Drug: Vitamin D3

First Posted Date: 2021-12-17

Last Posted Date: 2024-11-18

Lead Sponsor: Imperial College London

Target Recruit Count: 16

Registration Number: NCT05161351

Locations: 🇬🇧
Imperial College Healthcare Trust, London, United Kingdom

Inherited Cardiac cONditions In Kids

Recruiting

Conditions: Cardiovascular Diseases
Inherited Cardiac Conditions

First Posted Date: 2021-12-15

Last Posted Date: 2025-03-05

Lead Sponsor: Imperial College London

Target Recruit Count: 300

Registration Number: NCT05158738

Locations: 🇬🇧
Harefield Hospital, Uxbridge, United Kingdom
🇬🇧
Great Ormond Street Hospital for Children, London, United Kingdom
🇬🇧
Royal Brompton Hospital, London, United Kingdom

Trajectories and Mechanisms of Recovery From Malaria: An Observational Study

Active, not recruiting

Conditions: Malaria

First Posted Date: 2021-12-08

Last Posted Date: 2025-02-19

Lead Sponsor: Imperial College London

Target Recruit Count: 240

Registration Number: NCT05149157

Locations: 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom

Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies

Completed

Conditions: Solid Organ Transplant Recipients
Haematological Malignancies
Autoimmune Diseases

Interventions: Diagnostic Test: self-administered lateral flow assays

First Posted Date: 2021-12-08

Last Posted Date: 2024-12-09

Lead Sponsor: Imperial College London

Target Recruit Count: 28411

Registration Number: NCT05148806

Locations: 🇬🇧
Ipsos Mori, London, United Kingdom
🇬🇧
National Disease Registration Service, London, United Kingdom
🇬🇧
NHS Blood and Transplant, Bristol, United Kingdom

and more 1 locations

INTERvention With Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (INTERCEPTavi)

Not Applicable

Recruiting

Conditions: Aortic Valve Stenosis
Silent Cerebral Infarct
Vascular Brain Injury
Stroke

Interventions: Other: Saline flushing
Other: CO2 and saline flushing

First Posted Date: 2021-12-06

Last Posted Date: 2023-01-26

Lead Sponsor: Imperial College London

Target Recruit Count: 120

Registration Number: NCT05146037

Locations: 🇬🇧
Imperial College London, London, United Kingdom

Clinical Outcomes of Single Stage Versus Two-stage Treatment of Severe Obesity

Completed

Conditions: Obesity, Morbid

Interventions: Procedure: Gatsric balloon insertion

First Posted Date: 2021-12-06

Last Posted Date: 2021-12-06

Lead Sponsor: Imperial College London

Target Recruit Count: 155

Registration Number: NCT05146011

METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia

Phase 2

Recruiting

Conditions: Cognitive Impairment
Cognitive Decline
Dementia

Interventions: Other: Self-guided multidomain lifestyle intervention
Combination Product: FINGER 2.0 multidomain lifestyle-based intervention

First Posted Date: 2021-11-05

Last Posted Date: 2024-02-06

Lead Sponsor: Imperial College London

Target Recruit Count: 600

Registration Number: NCT05109169

Locations: 🇫🇮
Finnish Institute of Health and Welfare - THL, Helsinki, Finland
🇸🇪
Karolinska Institutet, Solna, Sweden
🇬🇧
Ageing Epidemiology Research Unit, Imperial College London, London, United Kingdom

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3

Recruiting

Conditions: Lung Cancer, Nonsmall Cell

Interventions: Drug: Pembrolizumab 25 MG/ML [Keytruda]

First Posted Date: 2021-10-20

Last Posted Date: 2024-03-07

Lead Sponsor: Imperial College London

Target Recruit Count: 1750

Registration Number: NCT05085028

Locations: 🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom
🇬🇧
Royal Bournemouth Hospital, Bournemouth, United Kingdom
🇬🇧
Royal Sussex County Hospital, Brighton, United Kingdom

and more 34 locations

Addition of Probenecid to Penicillin-V Therapy

Phase 1

Completed

Conditions: Infection, Bacterial

Interventions: Drug: Probenecid

First Posted Date: 2021-10-19

Last Posted Date: 2025-01-30

Lead Sponsor: Imperial College London

Target Recruit Count: 21

Registration Number: NCT05082909

Locations: 🇬🇧
Imperial Clinical Research Facility, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy